NWBO Northwest Biotherapeutics Inc

  1. Stocks
  2. Healthcare
  3. OTC: NWBO

Price (delayed)

$0.5

Market cap

$594.99M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.06

Enterprise value

$638.42M

Highlights
The equity has grown by 49% YoY
NWBO's net income is up by 40% year-on-year and by 13% since the previous quarter
Northwest Biotherapeutics's revenue has increased by 15% YoY but it has decreased by 7% QoQ
The company's gross profit rose by 15% YoY but it fell by 7% QoQ
NWBO's debt has soared by 74% YoY and by 22% QoQ
Northwest Biotherapeutics's quick ratio has plunged by 58% from the previous quarter and by 17% YoY
Sector: Healthcare
Industry: Biotechnology
Website: https://nwbio.com/
Peers: CLDX AMGN AGEN BMY

Key stats

What are the main financial stats of NWBO
Market
Shares outstanding
1.19B
Market cap
$594.99M
Enterprise value
$638.42M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
289.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
330.44
Earnings
Revenue
$1.93M
EBIT
-$57.36M
EBITDA
-$55.63M
Free cash flow
-$57.07M
Per share
EPS
-$0.06
Free cash flow per share
-$0.05
Book value per share
-$0.06
Revenue per share
$0
TBVPS
$0.02
Balance sheet
Total assets
$27.87M
Total liabilities
$74.92M
Debt
$45.56M
Equity
-$65.77M
Working capital
-$41.08M
Liquidity
Debt to equity
-0.69
Current ratio
0.09
Quick ratio
0.05
Net debt/EBITDA
-0.78
Margins
EBITDA margin
-2,879.1%
Gross margin
100%
Net margin
-3,240.1%
Operating margin
-2,873.1%
Efficiency
Return on assets
-213.4%
Return on equity
N/A
Return on invested capital
-362.9%
Return on capital employed
N/A
Return on sales
-2,968.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NWBO stock price

How has the Northwest Biotherapeutics stock price performed over time
Intraday
-1.09%
1 week
-3.46%
1 month
-5.66%
1 year
-7.63%
YTD
-28.67%
QTD
-3.66%

Financial performance

How have Northwest Biotherapeutics's revenue and profit performed over time
Revenue
$1.93M
Gross profit
$1.93M
Operating income
-$55.51M
Net income
-$62.6M
Gross margin
100%
Net margin
-3,240.1%
NWBO's net margin is up by 48% YoY and by 6% QoQ
NWBO's net income is up by 40% year-on-year and by 13% since the previous quarter
NWBO's operating margin is up by 28% year-on-year but it is down by 2.3% since the previous quarter
NWBO's operating income is up by 17% YoY and by 5% from the previous quarter

Growth

What is Northwest Biotherapeutics's growth rate over time

Valuation

What is Northwest Biotherapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
289.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
330.44
The EPS has grown by 40% YoY
The equity has grown by 49% YoY
The P/S is 39% below the 5-year quarterly average of 475.9 and 25% below the last 4 quarters average of 386.7
Northwest Biotherapeutics's revenue has increased by 15% YoY but it has decreased by 7% QoQ

Efficiency

How efficient is Northwest Biotherapeutics business performance
The ROS has grown by 50% YoY and by 7% from the previous quarter
The return on assets rose by 39% year-on-year and by 10% since the previous quarter

Dividends

What is NWBO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NWBO.

Financial health

How did Northwest Biotherapeutics financials performed over time
The total assets is 63% smaller than the total liabilities
Northwest Biotherapeutics's quick ratio has plunged by 58% from the previous quarter and by 17% YoY
The current ratio has declined by 47% since the previous quarter but it is up by 29% year-on-year
NWBO's debt is 169% higher than its equity
NWBO's debt has soared by 74% YoY and by 22% QoQ
The equity has grown by 49% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.